Skip to content
Medical Health Aged Care, Research Development

MEDIA RELEASE: Cancer Council ACT announces the 2025 Cancer Research Grant Recipients at Government House

Cancer Council ACT 2 mins read
 

On Thursday 29 May, Her Excellency the Honourable Sam Mostyn AC, Governor-General of the Commonwealth of Australia, and Patron of Cancer Council ACT, hosted a special Australia’s Biggest Morning Tea event at Government House for volunteers, supporters and researchers.  

At the event, Dr. Di Wang and Dr. Olga Zaytseva, both from the Australian National University (ANU), were officially announced as the 2025 Cancer Council ACT Research Grant recipients. 

Dr. Wang received the grant for his project titled "Harnessing RNA-Protein Interactions for the Regulation of Hepatocellular Carcinoma Progression". His project aims to design small molecules to control specific cancer-promoting genes in order to improve therapies for people living with liver cancer. 

“With the support of this grant, we will build on our understanding of these RNA hairpin structures and also investigate the potential of small molecules to bind and stabilise these elements,” said Dr. Wang. 

The hope is that “this will restore their ability to regulate MAT2A through the target mRNA, which plays a key role in hepatocellular carcinoma (HCC) development.”  

“I gratefully acknowledge the support from Cancer Council ACT, which has been instrumental in advancing this research project.” 

Dr. Zaytseva was awarded the grant for her research into "Rational approaches to identify new treatments for primary brain cancer." Her project aims to identify new drugs effective at killing brain cancer cells, by specifically targeting their energy production which is disrupted compared to normal cells. 

"Studying brain cancer cells collected via the ACT Brain Cancer Biobank that closely resemble patient tumours, we will maximise chances that our findings will ultimately inform effective tumour treatments.” 

Dr. Zaytseva’s research is further strengthened by collaboration with the Canberra Hospital, connecting laboratory researchers with the clinicians and creating a direct pipeline from laboratory discoveries to potential clinical applications. 

“We are thrilled to support Dr Wang and Dr Zaytseva’s innovative work, both of which have the potential to lead to meaningful advances in cancer treatment right here in the ACT. This progress is made possible by the generosity of our community and fundraising efforts like Australia’s Biggest Morning Tea,” said Verity Hawkins, CEO of Cancer Council ACT. 

Canberrans are encouraged to host their own Australia’s Biggest Morning Tea events until the end of June.  


Key Facts:

*Cancer Council ACT has awarded two grants of $75,000 to Dr Di Wang and Dr. Olga Zaytseva both from the John Curtin School of Medical Research at the ANU.

*The projects funded include research into liver cancer therapies and identifying effective drugs to combat brain cancer.

*The awards were hosted at Government House by Her Excellency the Honourable Sam Mostyn AC, Governor-General of the Commonwealth of Australia, and Patron of Cancer Council ACT

*Cancer Council relies on community fundraising to fund these research grants, and is encouraging Canberrans to host a Biggest Morning Tea.


About us:

Cancer Council ACT has been advocating for Canberrans living with cancer for more than 50 years across every aspect of cancer prevention, support and research to alleviate the impact of cancer in the community. Learn more about what we do here. 


Contact details:
 

Cancer Council ACT 

[email protected] 

Ph: 02 6257 9999 

Media

More from this category

  • Medical Health Aged Care
  • 13/05/2026
  • 23:10
Wellgistics Health, Inc.

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030,…

  • Contains:
  • Medical Health Aged Care
  • 13/05/2026
  • 22:10
Sapu Bioscience, LLC

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle(TM) Formulation of Everolimus

First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCCSAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sapu Nano today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, the Company’s investigational intravenous Deciparticle™ formulation of everolimus.The trial: SP-03-B101 — Sapu003 in Patients with Advanced mTOR-sensitive Solid Tumors (NCT07369505), is a Phase 1b, open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The investigational product is administered…

  • Medical Health Aged Care
  • 13/05/2026
  • 17:33
Palliative Care Australia

Budget a welcome step towards fairer end-of-life care

Palliative Care Australia has welcomed Australian Government Budget announcements that will improve support for people receiving end-of-life care at home, while calling for further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.